

UNITED STATES PATENT AND TRADEMARK OFFICE  
Trademark Trial and Appeal Board  
P.O. Box 1451  
Alexandria, VA 22313-1451

Mailed: February 10, 2012

Opposition No. 91192781

Bayer HealthCare LLC

v.

Biogen Idec MA Inc. and  
Cardiokine Biopharma, LLC

**George C. Pologeorgis,  
Interlocutory Attorney:**

Opposer's consented motion (filed February 9, 2012) to suspend this proceeding for thirty days so that the parties may pursue settlement is granted to the extent noted below.

Proceedings herein are suspended up to, and including, **March 10, 2012**, subject to the right of either party to request resumption at any time. See Trademark Rule 2.117(c).

In the event that there is no word from either party concerning the progress of their negotiations, upon conclusion of the suspension period, proceedings shall resume without further notice or order from the Board, upon the schedule set out below.

Proceedings resume:

**March 11, 2012**

Plaintiff's Pretrial

Disclosures

**4/10/2012**

Plaintiff's 30-day Trial Period

Ends

**5/25/2012**

Defendant's Pretrial Disclosures	6/9/2012
Defendant's 30-day Trial Period Ends	7/24/2012
Plaintiff's Rebuttal Disclosures	8/8/2012
Plaintiff's 15-day Rebuttal Period Ends	9/7/2012

In each instance, a copy of the transcript of testimony together with copies of documentary exhibits, must be served on the adverse party within thirty days after completion of the taking of testimony. Trademark Rule 2.125.

Briefs shall be filed in accordance with Trademark Rules 2.128(a) and (b). An oral hearing will be set only upon request filed as provided by Trademark Rule 2.129.

If, during the suspension period, either of the parties or their attorneys should have a change of address, the Board should be so informed.